NCT06334757 2024-03-28
Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure
Henan Cancer Hospital
Phase 2 Unknown
Henan Cancer Hospital
Innovent Biologics (Suzhou) Co. Ltd.
Hoffmann-La Roche
Genentech, Inc.
Genentech, Inc.
Hoffmann-La Roche
Hoffmann-La Roche